Alpine Immune Sciences Inc (NQ: ALPN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 64.33 (1)
Ask (Size) 65.64 (1)
Prev. Close 64.97
Today's Range N/A - N/A
52wk Range 10.80 - 64.98
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Via Benzinga
ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024
ALPN stock results show that Alpine Immune Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

More News

Read More
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
Via InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 4/16
Via Investor Brand Network
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
From Kahn Swick & Foti, LLC
Via Business Wire
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Via Benzinga
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Via The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
Via The Motley Fool
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Via InvestorPlace
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Via The Motley Fool
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Stocks Surge, Goldgasms To Record High After "Adjusted" PPI Sparks Buying Frenzy
Via Talk Markets
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.